DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Virtual Training Course (US Eastern Time)

2020 年 10 月 12 日 9:00 上午 - 2020 年 10 月 14 日 4:30 下午

Drug Safety and Pharmacovigilance Across the Product Lifecycle

Build a solid foundation in the key concepts of drug safety and pharmacovigilance throughout the medical product development lifecycle. In this live virtual training, learn how to comply with regulatory requirements.

概览

In this comprehensive live virtual training course learn contemporary principles, regulatory expectations, and practical approaches to drug safety and pharmacovigilance in key regulatory jurisdictions, with a focus on the US and EU. The course curriculum is designed for the basic to intermediate level professional, and the topics will span the lifecycle of traditional innovative medicinal products, from first-in-human through the post-marketing phase. This blended learning course employs a mixture of pre-course online learning, informative instructional sessions, real-world case studies, and hands-on interactive exercises where learners can apply what they learn.

 

内容纲要

  • Legal and regulatory basis for safety obligations, including a historical perspective
  • Principles, basic definitions, and pragmatic approaches for compliance
  • Basics of Individual Case Safety Reports (ICSRs) and periodic reports (DSUR, IND AR, PADER, PSUR/PBRER) in the pre-marketing, peri-approval, and post-marketing continuum  
  • Evaluation of seriousness, expectedness and causality
  • Data collection, processing, and requirements in the post-marketing phase, including MedDRA coding, safety query development, and evolving regulatory requirements
  • Overview of case processing and organization of a typical safety department
  • Safety audits and inspections
  • Introduction to signal detection
  • Introduction to benefit-risk assessment
  • Basics of risk management planning, EU Risk Management Plans, and Risk Evaluation and Mitigation Strategies (REMS)

谁应该参加?

This program is designed for entry through intermediate level professionals involved in:

  • Drug safety/pharmacovigilance
  • Adverse event reporting
  • Case processing
  • Safety evaluation
  • Periodic safety reporting
  • Medical monitoring
  • Quality systems
  • Regulatory strategy, regulatory affairs
  • Risk management planning and development of formal Risk Management Plans and REMS
  • Disciplines that interact with or support safety and pharmacovigilance functions across the product lifecycle

Broadening their role within pre-market or post-market safety and pharmacovigilance functions

学习目标

At the conclusion of this activity, participants should be able to:

  • Identify the history, principles, and regulatory framework for clinical trials and post-marketing safety
  • Evaluate the basic definitions of terms used in day-to-day pharmacovigilance work
  • Recognize basic international regulatory requirements for safety surveillance, as well as those requirements specific for the US and EU
  • Cite the criteria and elements of expedited and periodic reporting of drug safety information from first-in-human studies through the post-marketing phase
  • Define of risk management and signal detection principles

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。